ProductDescription
VitroCol®collagenisthefirstwidelyavailable,naturallyproducedpurifiedhumancollagenforresearchpurposes.VitroCol®setsthestandardforpurity(>99%collagencontent),functionalityandrepresentstheonlynative-likehumancollagenoffered.
VitroCol®collagenisnaturallysecretedfromhumanneo-natalfibroblastcells.Thehumanfibroblastsareculturedinoptimalconditionsallowingthefibroblasttonaturallyandefficientlysecretextracellularmatrix.Theextracellularmatrixisthenprocessedandpurifiedtoyieldthenaturallyproducedhumancollagen.
VitroCol®isapproximately97%TypeIhumancollagenwiththeremainderbeingcomprisedofTypeIIIcollagen.VitroCol®issuppliedatapproximately3mg/mlconcentration.TheconcentrationforeachspecificlotisprovidedonaCertificateofAnalysisthatisavailablewiththepurchaseofeachproduct.VitroCol®issolubleatelocollagenin0.01NHCI,therefore,thepHis2.
VitroCol®isespeciallyidealforhumancellculturesystemswhencoatingofsurfaces,providingpreparationsofthinlayersofculturingcells,oruseasasolidgel.VitroCol®humancollagenisprovidedinuser-friendlypackagingforuseandstorage.VitroCol®issterilefilteredandissuppliedasareadytousesolution.
| Parameter,Testing,andMethod | VitroCol®TypeICollagen#5007 |
| SterilizationMethod | Filtration |
| ExtractionMethod | Enzyme-atelocollagen |
| Form | Solution |
| PackageSize | 20mL,100mL |
| StorageTemperature | 2-10°C |
| ShelfLife | Minimumof6monthsfromdateofreceipt |
CollagenConcentration-Biuret | 2.9-3.2mg/mL |
CollagenPurity-SilverStaining | >99% |
| pH | 1.9-2.1 |
| KineticGelTest(Minutes) | <40 |
| GelFormationTubeTest(Minutes) | <40 |
Fibrillogenesis(AbsorbanceUnits) | >0.5 |
ElectrophoreticPattern-CoomassieBlue | Characteristic |
| Sterility-USPmodified | Nogrowth |
| Endotoxin-LAL | <5.0EU/mL |
| Osmolality(mOsmoH2O/kg) | <35 |
| CellAttachmentAssay | Pass |
| Source | HumanNeo-NatalFibroblasts |
| HydrogelYoung"sModulusE(Pa) | Characteristic |
DirectionsforUse
DownloadthefullPDFversionorcontinuereADIngbelow:
CoatingProcedure
Note:Usetheserecommendationsasguidelinestodeterminetheoptimalcoatingconditionsforyourculturesystem.
- Transferdesiredvolumeofcollagensolutionfromthebottletoadilutionvesselasrequired.Dilutetodesiredconcentrationusingsterile0.01NHClsolution.Atypicalworkingconcentrationmayrangefrom50to100ug/ml.
- AddappropriateamountofdilutedVitroCol®materialtotheculturesurface.
- Incubateatroomtemperature,covered,for1-2hours.Aspirateanyremainingmaterial.Alternatively,incubateatroomtemperatureuntilsurfaceisdry.
- RinsecoatedsurfacescarefullywithsterilemediumorPBS,avoidscratchingsurfaces.
- Coatedsurfacesarereadyforuse.Theymayalsobestoredat2-8°Cdamporairdriedifsterilityismaintained.
3-DGelPreparationProcedure
- Slowlyadd1partofchilled10XPBSor10Xculturemediato8partsofchilledcollagensolutionwithgentleswirling.
- AdjustpHofmixtureto7.0-7.5usingsterile0.1MNaOH.MonitorpHadjustmentcarefully(pHmeter,phenolred,orpHpaper)
- Adjustfinalvolumetoatotalof10partswithsterilewater.
- Topreventgelation,maintaintemperatureofmixtureat2–10°C.
- Toformgel,warmto37°C.Allowapproximately90to120minutesforgelformation.
ProductQ&A
WecompletedastudytoshowthatDNAiscompletelydestroyedatpH2,anddemonstratedthatourcollagenproductsdonotcontainDNA.
Thecollagenisfullyhydrolyzed.TheaminoacidanalysisisdoneusingtheWatersAccQ-Tagderivatizationmethod.Duringtheacidhydrolysisstep,asparagine(N)isconvertedtoasparticacid(D)andglutamine(Q)isconvertedtoglutamicacid(E).Tryptophan(W),ifpresent,isdestroyedduringacidhydrolysis.Experimentally,onecandeterminethepicomoles(pmol)ofeachaminoacidperinjecteddetectedusingaminoacidstandards.Fortheconcentrationdetermination,thetotalnumberofpmolofeachaminoacidissummedtogetthetotalpmolofthe18aminoacidsdetected.Thetotalpmolaminoacidsisdividedbythetheoreticalnumberofaminoacidresiduesincollagenbasedonthepublishedsequence.Theresultisthepmolofcollageninjected.Theresultisthenmultipliedbythedilutionand300,000isusedasthecollagenmolecularweighttogettomg/mL.Themolecularweightofcollagenisnotwellagreedupon.
Dilutingwith1XPBS(ratherthanwateror0.01NHCl)wouldhaveaneffectforcoatingpurposes.ItwouldchangethepHofthedilutedcollagensolutionfromacidtoneutralpH.ThepHchangewilltransformthecollagenmoleculesfromamolecularformtoafibrillarform;andthenthenatureofcoatingsurfacewillbechangedfromamonomericcoatingtoafibrillarcoating.
WeusethefollowingantibodiesfromSouthernBiotech:
1.1310-02–GoatAnti-TypeICollagen-FITC
2.1310-08–GoatAnti-TypeICollagen-BIOT
3.7100-05–Streptavidin-HRP
ThemajorcollagenmolecularspeciesinourTypeIcollagenproductsaremonomers(approx.70%),buttherearedimers,trimersandafewpercentagesofoligomerstoo(approx.30%)withsomeminoramountsofcollagenfragments.Thecollagenmonomerisarodshapedmoleculewith300nminlengthand1.5nmindiameter.Thedimer,trimerandoligomerare600nm,900nmandevenlongerinlengthrespectively.Accordingtothecoatingprocedures,thecollagenmoleculesareattachedtothechargedpolystyrenesurfacerandomlybychargeoraffinityinacidconditionsduringthe1-2hrsincubationperiodat37°C,andanyunattachedmaterialsareremovedbyaspirationandrinsing.Therefore,thecoatedsurfaceisasinglelayerofcollagenmonomer,dimer,trimerandoligomermixtures.Thethicknessofthemono-molecularlayerisdependentonhowthosemoleculesareattachedonthesurface.Thecoatingdensitythicknesswouldgenerallybecharacterizedasa1moleculethicknesswhichcouldberangingfromafewnanometerstoafewhundrednanometerswiththewholesurfacebeingcoveredbycollagen.
ThenetchargeofTypeIcollagenproducts’(PureCol®,BovineCollagenandVitroCol®,HumanCollagen)moleculeisdirectlyrelatedtothepH.AtanacidicpH,theaminoacids(zwitterions)alongthecollagenmoleculearepositivelycharged,makingtheentirecollagenmoleculepositive.Attheisoelectricpoint(orzone)ofcollagen,aroundpH7-8,theaminoacidsalongthecollagenmoleculearepositivelyandnegativelycharged,makingthenetchargeofthecollagenmoleculeclosetozero.AtabasicpH,theaminoacidsalongthecollagenmoleculewerenegativelycharged,makingtheentirecollagenmoleculenegative.
Further,thenatureofthechargeofthecollagencoatingsurfacewillbedependentonthetypeofcoatingapplied.ForamonomericcollagencoatingswhenthecollagenisappliedunderanacidicpHcondition,thesurfaceispositivelycharged.IfthesurfaceisrinsedwithpHneutralbufferormediathenitwillchangethechargeofthecollagensurfacenetchargeclosetozero.Fora3Dgelcoating,thecollagenpreparedunderneutralpH;thenetchargeofthecollagensurfaceisclosetozero.
Usingrotaryshadowingtechniqueundertransmissionelectronmicroscopy,itwasfoundthatourcollagen,onaverage,consistsofapproximately80%monomers,13%dimers,trimers,andoligomerswiththeremaining7%collagenfragments.
Yes.ThecollagenmoleculeinPureCol,Nutragen,VitroCol,andallofourotherAtelocollagenproductswerepreparedfromnativecollagenmatrixbypepsintreatmentundercontrolledconditionstoremovethenon-helicalportion,telo-peptides,onlyandthehelicalportionisintact.Inthiscase,theenzymaticactivesitesforMMP(MatrixMetalloproteinase),suchasforMammalianCollagenaseMatrixMetalloproteinase8(MMP-8),onthemoleculewaspreserved.
Thesepepsintreatedcollagenproductsshouldbehaveasnativeintactcollagen.
TGFbetawouldhavebeendigestedwiththepepsinenzymaticdigestionstep.ItwasundetectablebySDSPAGEsilverstainaswell.Wedidn’tdoanyspecificmeasurementsbyELISAhoweverbutpresencesofTGFbetaisnotanticipated.
WeprimarilyusetheBiuretmethod,butwealsouseBCA,AAA,andhydroxyl-prolineassays.
-Collagensolutionsthatarefrozentendtohaveissuesforming3Dhydrogels,andwilllikelynotwork.Thesolutionsshouldstillbegoodfor2Dcoatings.
-Collagensolutionsthatareleftoutatroomtemperatureforextendedperiodsoftimemayshowsignsofdegradation,whichwillaffecttheformationof3Dhydrogels.Itislikelystillfinefor2Dcoatings.
Ourrecommendationisthis:Ifyouareusingtheproductdirectlyforapublication,wehighlysuggestbuyinganewbottleiftheoneyouhavewascompromised.
ProductReferences
ReferencesforVitroCol®:
Andrée,B.etal.Formationofthree-dimensionaltubularendothelialcellnetworksunderdefinedserum-freecellcultureconditionsinhumancollagenhydrogels.ScientificReports9,(2019).
Shieh,HesterF.,etal."ComparisonsofhumanamnioticmesenchymalstemcellviABIlityinFDA-approvedcollagen-basedscaffolds:Implicationsforengineereddiaphragmaticreplacement."Journalofpediatricsurgery52.6(2017):1010-1013.
vanderVelden,JosLJ,etal."TransformingGrowthFactor-ßInducesAMesenchymalProfileInHumanNasalEpithelialCells."D76.ALVEOLAREPITHELIUM:NOVELTOOLSANDPHENOTYPES.AmericanThoracicSociety,2012.A6322-A6322.
Tashima,Takumi,etal."Osteomodulinregulatesdiameterandaltersshapeofcollagenfibrils."Biochemicalandbiophysicalresearchcommunications463.3(2015):292-296.
Spiller,KaraL.,SuzanneA.Maher,andAnthonyM.Lowman."Hydrogelsfortherepairofarticularcartilagedefects."TissueengineeringpartB:reviews17.4(2011):281-299.
Brilha,Sara,etal."Monocyteadhesion,migration,andextracellularmatrixbreakdownareregulatedbyintegrinαVβ3inMycobacteriumtuberculosisinfection."TheJournalofImmunology199.3(2017):982-991.
Jonsdottir,HuldaR.,andRonaldDijkman."Characterizationofhumancoronavirusesonwell-differentiatedhumanairwayepithelialcellcultures."Coronaviruses.HumanaPress,NewYork,NY,2015.73-87.
Sabbione,Florencia,etal."Neutrophilextracellulartrapsstimulateproinflammatoryresponsesinhumanairwayepithelialcells."Journalofinnateimmunity9.4(2017):387-402.
DosSantosBrilha,S.,etal."Monocyteadhesion,migrationandextracellularmatrixbreakdownisregulatedbyintegrinαVβ3inMycobacteriumtuberculosisinfection."
Brilha,Sara,etal."MonocyteAdhesion,Migration,andExtracellularMatrixBreakdownIsRegulatedbyIntegrinaVb3inMycobacteriumtuberculosisInfection."(2017).
Colace,T.,etal."Analysisofmorphologyofplateletaggregatesformedoncollagenunderlaminarbloodflow."Annalsofbiomedicalengineering39.2(2011):922-929.
Muthard,RyanW.,andScottL.Diamond."Bloodclotsarerapidlyassembledhemodynamicsensors:flowarresttriggersintraluminalthrombuscontraction."Arteriosclerosis,thrombosis,andvascularBIOLOGy32.12(2012):2938-2945.
Maloney,S.F.,LawrenceF.Brass,andS.L.Diamond."P2Y12orP2Y1inhibitorsreduceplateletdepositioninamicrofluidicmodelofthrombosiswhileapyraselacksefficacyunderflowconditions."IntegrativeBiology2.4(2010):183-192.
Bauer,RebeccaN.,etal."Interactionwithepithelialcellsmodifiesairwaymacrophageresponsetoozone."Americanjournalofrespiratorycellandmolecularbiology52.3(2015):285-294.
Kawamura,Shunsuke,etal."IdentificationofcommonmonocyteProgenitors,pre-monocytes,andgranulocytemonocyteprogenitorsinhumanumbilicalcordblood."ExperimentalHematology43.9(2015):S72.
ProductCertificateofAnalysis
SafetyandDocumentation
SafetyDataSheet
CertificateofOrigin
ProductDisclaimer
ThisproductisforR&Duseonlyandisnotintendedforhumanorotheruses.PleaseconsulttheMaterialSafetyDataSheetforinformationregardinghazardsandsafehandlingpractices.
美国AdvancedBioMatrix（简称ABM） www.advancedbiomatrix.comAdvancedBioMatrix（简称ABM）是美国一家著名的生物公司，获得了AllerganInc的授权(Allergan用25年时间不断完善胶原蛋白相关的产品的生产工艺)，将Allergan的专业和技术用于蛋白生产与检测，致力于为组织工程、细胞分析及细胞增殖等研究领域提供优质稳定的产品。AdvancedBioMatrix不断丰富已有产品线，目前可为三维细胞培养提供各种胶原蛋白、纤连蛋白、玻连蛋白、水性凝胶、不同粘度与分子量的透明质酸以及低代成纤维细胞等。在美国全部产品授权Sigma销售。AdvancedBioMatrix是组织培养，细胞分析和细胞增殖三维（3D）应用的生命科学领域的领导者。我们的产品被公认为纯度，功能性和一致性的标准。我们在生产，分离，纯化，冷冻干燥，细胞培养和蛋白质测试，粘附肽，附着因子，底物刚性和其他3D矩阵产品方面拥有丰富的专业知识。我们的专业技术和知识正在被用来确保我们的产品质量最高，批次之间一致且易于为我们的研究客户使用。
美国AdvancedBioMatrix是3D组织培养、细胞检测和细胞增殖等领域实验解决方案的佼佼者。AdvancedBioMatrix在分离、纯化、冻干、细胞培养和蛋白检测、多肽粘附、附着因子、基质硬度和其他3Dmatrix 产品开发方面有着丰富的经验。AdvancedBioMatrix的研发经验和专业知识确保其产品可达到最佳质量，并保证产品之间一致性，方便研究客户使用。以下为AdvancedBioMatrix3DMatrices 产品竞争优势：1. 提供高纯度和成分确定的胞外基质；2. 超过1000余篇文献引用PureCol产品，品质非常均一；3. 在3D培养基领域可提供最全面的产品线；4. 唯一可提供特异性刚性有机硅基板的公司（CytoSoft）;5. 唯一可提供可溶性丝纤蛋白的供应商（可运用于多种3D培养）；6. 如果客户首次接触3D胶原凝胶，AdvancedBioMatrix还是唯一的预制胶原蛋白(PureColEZGel)供应商；
以下产品为AdvancedBioMatrix全球畅销品：1.PureCol 牛源I型胶原蛋白 3mg/ml#5005-100ML2.Nutragen牛源I型胶原蛋白 6mg/ml#5010-50ML3.FibriCol 牛源I型胶原蛋白 10mg/ml#5133-20ML4.VitroCol 人源I型胶原蛋白 #5007-20ML5. 弹性蛋白原 #5052-1MG6.ECMSelectArraykitUltra-36#5170-1EA7.CytoSoft（刚性可变的基底，AdvancedBioMatrix最新添加产品5190-7EA）8. 人III型胶原蛋白 #5021-10MG9. 人IV型胶原蛋白 #5022-5MG10.SilkFibroin溶液 #5154-20ML11.Fibronectin#5080-5MG12.Vitronectin#5051-0.1MG
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
我们一般是在心导管室内，要在特殊的X线设备，可以转动的C臂心血管造影机，影像增强设备和电视荧屏设备，多导电生理记录仪，心脏程控刺激仪等。高档可以有三维电解剖生理定位标测系统比如CARTO，EnSite3000，这仅仅国内少数顶尖医院才有。
我们做电生理检查是通过你自身的血管放入心导管，直到心脏相应部位，一般主要局部麻醉，小孩则需要全麻。手术前必须停用抗心律失常药物至少5个半衰期以上，一般至少要3天，一般抗凝药物也是需要停用的。
我们局部需要手术前备皮，也就是局部皮肤清洁，有毛发的也需要清理干净。然后铺上洞巾。仅仅暴露局部血管穿刺部位。
我们穿刺血管插入诱发电极导管是根据不同需要来的，比如通常我们需要至少放置冠状静脉窦电极，右心室电极，高位右心房电极，和His束电极，那么冠状静脉窦电极是一般通过左锁骨下静脉或者右颈内静脉穿刺放置的，而右心室、高右房和His束电极则通过右股静脉放置。这些和体表心电图构成都可以让医生在电视屏幕上看到你不同的心电图图形，这样可以更加明确你心律失常的机制，部位。那么我们就可以标定你需要消融的部位（靶点）
我们通过插入电极导管，然后我们就进行心电生理检查，也就是人工给与各种电刺激，诱发你心律失常，比如我们可以采用输出电刺激信号比如用S1S1 刺激，也可以采用S1S2刺激等等，有时候可以静脉点滴异丙肾上腺素等药物，增加诱发的成功率，术前我们停用抗心律失常药物也是这个目的，就是诱发出你心律失常，这样我们根据体表和心内心电图，可以准确判断并定位你心律失常发生机制和部位，为下一步射频导管消融作准备，其实标定，是最为关键的一步，你只有找准敌人才能准确打击。准确的标定，也就是找准敌人的位置，那么就为打击敌人，做出关键的作用。我们的射频导管就像导弹一样，但是你必须先直到敌人在哪里，把它标定好，然后我们的导弹就可以直接定点清除。
目前比较新的高档的比如CARTO，就是类似于全球定位系统GPS的原理，可以准确三维立体定位你心律失常形成的部位和路径。一般我们针对最多是折返造成的心律失常，比如最多用于房室结双径路或者房室旁路引起的阵发性室上速，成功率一般是95%以上。
如果是房扑，主要是经典房扑，那么一般我们需要用一个Halo导管，一根可以弯折的上面带有很多对电极的导管，沿着折返环，环形放置。那么成功率也可以到95%。
首先导管插入部位（腹股沟、手臂、肩膀或颈部）的皮肤消毒，局麻药进行局部麻醉；然后用穿刺针穿刺静脉/动脉血管，电生理检查导管通过血管插入心腔；心脏电生理检查所用的电极导管长而可弯的导管，能将电信号传入和传出心脏。电极导管记录心脏不同部位的电活动，并发放微弱的电刺激来刺激心脏，以便诱发心律失常，明确心动过速诊断；然后医生通过导管找到心脏异常电活动的确切部位（此过程称为“标测”），再通过消融仪发送射频电流消融治疗，从而根治心动过速。 血管穿刺并发症包括局部出血、血肿、感染、气胸、血栓形成、栓塞等，导管操作并发症包括主动脉瓣返流、心肌穿孔、心包填塞等，放电消融并发症包括房室传导阻滞、心肌梗死等。向左转|向右转
我现在手头上有“医疗器械分类规则（局令第15号）”单位没有说ⅠⅡⅢ类的事情？请教!
唉,我去成都军区总医院问了,那没这种手术的设备`````````
希望能有知道的人解答一下
磁共振 CT 脑电图 多普勒 肌电图 诱发电位 脑脊液检查 血液检查。。。。。。。。。。。。
心内科
心脏电生理记录系统、有创血压监测系统、心脏射频消融仪、心电分析系统、多参数监护仪、医疗网络产品等。
产品主要用于心脏射频消融、心脏电生理检查、冠脉造影、经皮冠状动脉成型术、支架植入、二尖瓣球囊扩张等心脏介入手术；人体生理参数监测；心电图分析等
